Lineage Q2 2022 Earnings Report
Key Takeaways
Lineage Cell Therapeutics reported a revenue of $4.6 million for the second quarter of 2022, primarily from licensing fees, royalties, collaboration revenues, and research grants. The net loss attributable to Lineage was $6.8 million, or $0.04 per share.
Progress made on RG6501 (OpRegen) product development under collaboration with Roche and Genentech.
Focus on completing clinical, regulatory and related activities to create value and reduce risk across portfolio of five cell transplant assets.
Preparing for OPC1 and VAC2 regulatory interactions to enable their next phases of clinical testing in spinal cord injury and oncology, respectively.
Advancing auditory neuron and photoreceptor programs through preclinical development activities necessary to support initial clinical testing.
Lineage
Lineage
Forward Guidance
Cash, cash equivalents, and marketable securities totaled $72 million as of June 30, 2022, which is expected to support operations through Q2 2024.